McKenna's Pharmacology for Nursing, 2e

974

Index

Antiviral agents continued herpes and cytomegalovirus, 132–134 adverse effects, 133 care considerations, 134 contraindications and cautions, 133 cytomegalovirus (CMV), definition, 126, 132 cytomegalovirus immunoglobulin, 286 drug–drug interactions, 133–134 herpes, definition, 126, 132 pharmacokinetics, 133 therapeutic actions and indications, 132 HIV and AIDS, 126, 128 agents for, 127, 134–144 care considerations, 142 CCR5 coreceptor antagonist, 126, 136, 141 critical thinking scenario, 143–144 education, 138 integrase inhibitor, 126, 136, 141–142 non-nucleoside reverse transcriptase inhibitors, 126, 136 nucleoside reverse transcriptase inhibitors, 126, 136–139 protease inhibitors, 126, 136, 139–140 influenza A and respiratory viruses, 126, 127, 130–132 adverse effects, 131 fixed combination drugs, 139 fusion inhibitor, 126, 136, 140

pharmacokinetics, 306 therapeutic actions and indications, 306 children, 304 miscellaneous drugs, 312–313 antihistamines, 313 buspirone, 313 chloral hydrate, 313 dexmedetomidine, 313

Atrioventricular block, 648 Atrium, 642, 643 Atropine, 501–503, 506–507, 956 atropine-like (anticholinergic) effects, 38 toxicity, 506 Attention-deficit disorders, 334, 336, 347 Auditory damage, 37–38 Auranofin, 252, 253 Auricle, 642, 643 Australian Drug Evaluation Committee (ADEC) drugs in pregnancy, classification, 9 Australian Prescriber , 12 Autism MMR vaccine and, 278 Autonomic nervous system, 444–453 adrenergic agonists. See Adrenergic agonists adrenergic blocking agents. See Adrenergic blocking agents anticholinergic agents. See Anticholinergic agents cholinergic agonists. See Cholinergic agonists function, 445–446 nerve impulse transmission, 445 parasympathetic nervous system, 444, 450–452 acetylcholine release, 451, 452 acetylcholine synthesis and storage, 451 blockade, effects, 505 Autoimmune disease, 228, 238 Automaticity, 642, 644–645, 697 cholinergic receptors, 451, 452 cholinergic response, 450–452 muscarinic receptors, 444, 451 nicotinic receptors, 444, 451 structure and function, 450 termination of response, 452 structure, 445–446 sympathetic nervous system, 444, 446–450 adrenergic receptors, 448 adrenergic response, 447–449 alpha-receptors, 444, 448 beta-receptors, 444, 448 blockers, 675–676 noradrenaline release, 448 noradrenaline synthesis and storage, 447–448 structure and function, 446–447 termination of response, 449 Autonomy, 190, 191 Axons, 292, 293, 295 Azacitidine, 200 Azathioprine, 260, 263, 264 Azelaic acid, 953 Azelastine, 853, 854, 953, 956 Azithromycin, 103, 122 Azole antifungals, 150, 151–157 adverse effects, 154 contraindications and cautions, 154

promethazine, 313 trimeprazine, 313

zolpidem, 313 zopicione, 313 older adults, 304 states affected by, 304–305 anxiety, 303, 304 hypnosis, 303, 305 sedation, 303, 304–305 Apixaban, 756, 759–760 Apomorphine, 374–376 Apple, 962 Apraclonidine, 956 Aprepitant, 199, 929, 932, 935 Arachidonic acid, 228, 231

ARC (AIDS-related complex), 126, 135 Aripiprazole, 335, 336, 338, 344, 345 Arnica, 962 Arrhythmias, 642, 647–648, 697–699 agents for. See Antiarrhythmic agents atrial, 698–699, 708 atrioventricular block, 648 automaticity, 697 conductivity, 697 haemodynamics, 697–698 sinus, 647–648 supraventricular, 648 types, 698–699 ventricular, 648, 699–701, 708 Arsenic trioxide, 195, 222 Artemether-lumefantrine 167 Arteries, 642, 643 Arthritis. See Antiarthritis agents Ascaris , 179, 180, 181 Ashwagandha, 962 Aspirin, 240–245, 751, 755, 758–759 Assessment, 42, 43–45 education level and understanding, 44 financial supports, 44 healthcare pattern, 44 history, 44 physical examination, 44–45 physical parameters, 45 social supports, 44 Asthma, 834, 839 Astragalus, 962 Atazanavir, 136, 139 Atelectasis, 834, 838 Atenolol, 469, 482–483, 675 Atheromas, 713, 714 Atherosclerosis, 713, 714 Atomoxetione, 347 Atorvastatin, 729, 734, 736, 737, 740–741 Atovaquone, 172, 173 Atracurium, 434, 435, 437 Atrial arrhythmias, 698–699, 708

care considerations, 131–132 contraindications and cautions, 130–131 drug–drug interactions, 131

pharmacokinetics, 130 therapeutic actions and

contraindications, 129, 130

locally active, 127, 146–147 adverse effects, 147 care considerations, 147

contraindications and cautions, 147 therapeutic actions and indications, 146 older adults, 128 Anxiety, 303, 304 Anxiolytic and hypnotic agents, 303–313 adults, 304 barbiturates used as anxiolytic/ hypnotics, 310–312 adverse effects, 311 care considerations, 312 contraindications and cautions, 311 drug–drug interactions, 311–312 pharmacokinetics, 310 therapeutic actions and indications, 310 benzodiazepines used as anxiolytics, 305–310 adverse effects, 307

care considerations, 307–308 contraindications and cautions, 306–307 drug–drug interactions, 307

drug–drug interactions, 154 pharmacokinetics, 153–154